In BxPC-3 tumor cells treatment with two of the used TLR ligands as well as LPS resulted in increased Bcl-xL expression (ODN: ROD = 109%, LPS: 140%, and HMGB1: 175%) (Figure 8A, right). The gene discussed is BCL2L1; the disease is neoplasm.